Navigation Links
Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
Date:5/18/2009

San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the ADHD Rating Scale-IV (ADHD-RS-IV), a scale frequently used in ADHD clinical trials. In results from this study presented today, INTUNIV also demonstrated sy
'/>"/>

Contact: Debra Gemme
debra.gemme@porternovelli.com
212-601-8342
Porter Novelli
Source:Eurekalert

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
2. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
3. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
4. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
5. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
6. Cipher receives tentative FDA approval for extended-release tramadol capsules
7. Bioniche Warrants Expiration Date to be Extended
8. Teaching Hospitals Post-Op Gains Not Extended to Blacks
9. Stroke therapy window might be extended past nine hours for some
10. Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio
11. Get Screened Video Contest Deadline Extended to Jan. 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013 VHA Inc., the national ... automated, provider-led population health improvement, announced a new ... and successfully pursue population health management with ... to accelerate the transition to value-based models of ... improvement suite of services, the offering integrates VHA ...
(Date:5/20/2013)... Washington, D.C., May 20, 2013 CosmosID, a leading data ... as part of a collaboration results on analysis of ... speed, specificity, and accuracy. , The Food and Drug ... number of commercially available probiotics, four of which have ... The purpose of the tests was to compare the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Finnish subjects and was led by Professor Samuli ... 28 genetic markers improved detection of individuals with ... risk ≥20%) over traditional risk factors. , Identification ... for CHD, because the current guidelines recommend statin ... that genetic markers could be useful in CHD ...
(Date:5/20/2013)... Dallas, TX (PRWEB) May 20, 2013 ... largest portfolio of employee benefit, payroll products and services ... announced that both are selected as finalists for the ... the Fastest-Growing Company of the Year category, and CompuPay ... Year. Each finalist will ultimately be a Gold, Silver ...
Breaking Medicine News(10 mins):Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
... , , ARLINGTON, ... Health and Human Services Office of Inspector General (OIG) ignored ... including complex rehab, to seniors and people with disabilities who ... the Medicare Program: Supplier Acquisition Costs and Services" and dated ...
... OKLAHOMA CITY, Sept. 3 Surgical Hospital of ... partnered with Surgical Care Affiliates (SCA), one of the country,s ... is a state of the art hospital providing surgical services ... pain management, podiatry and orthopedics. SCA and a number of ...
... done to protect young knees, ankles and shoulders, researcher says ... all high school sports injuries are bad enough to keep a ... the pack in severe injuries, a new U.S. study finds. , ... girls experienced a greater rate of severe injury than boys in ...
... worldunderstand and prepare for contagious outbreaks, the National Institutes ... adds new research expertise to increase its capacity to ... inform public health officials and policymakers. In ... and infected people around the world. In 2003, a ...
... delaying needed care ends up raising health-care costs, study ... -- Patients who don,t trust the health-care system are ... health and raising overall health care costs, a new ... majority of whom were black, about their attitudes toward ...
... , , , , ... entered into a definitive agreement under which Embla will acquire Covidien,s ... the Sandman(TM) brand name. Financial terms of the transaction were ... conditions. , , The combined entity will form ...
Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Surgical Hospital of Oklahoma to Partner with Surgical Care Affiliates 2Health News:High School Sports Put Players at Risk for Severe Injuries 2Health News:New grants expand US infectious disease modeling effort 2Health News:New grants expand US infectious disease modeling effort 3Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2
(Date:5/20/2013)... May 20, 2013  TNI BioTech, Inc. (OTCQB: TNIB), ... and mobilization of the body,s immune system using patented immunotherapy, ... Markets, OTCQB marketplace under the ticker symbol "TNIB" commencing ... real-time Level II stock quotes for TNIB at ... , CEO of TNI BioTech, Inc. stated, "We are ...
(Date:5/20/2013)...  Medicare Part D seniors in plans with ... costs, convenient access to pharmacies and other benefits, ... Associates released today by the Pharmaceutical Care Management ... seniors (9.5 million) are currently enrolled in plans ... lower costs, pharmacy choices, and overall value of ...
(Date:5/20/2013)... 2013 With herbal medicines relied upon by ... U.S. Pharmacopeial Convention (USP) will provide freely available public ... ingredients used in these products. Today, USP proposes the ... Herbal Medicines Compendium ( HMC ) for ... hmc.usp.org . HMC will provide standards ...
Breaking Medicine Technology:TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
... Data Showed Clinically Meaningful Benefits for Patients ... LONDON, May 29 ,GlaxoSmithKline (GSK) today announced ... the U.S. Food and Drug Administration and ... Rezonic(TM)/Zunrisa(TM) (casopitant), a novel,investigational NK-1 receptor antagonist. ...
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
Cached Medicine Technology:GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 2GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 3GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 4GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 5GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 6GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 7GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 8Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: